Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of ($6.75), $0.56 better than the analyst estimate of ($7.31). Revenue for the quarter came in at $7.8 billion versus the consensus estimate of $7.4 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.